Boots pre-close
This article was originally published in The Rose Sheet
Executive Summary
Boots Healthcare International second half sales jump about 13% at comparable exchange rates, UK company reports March 27 in a fiscal 2003 (ending March 31) 1pre-close statement. Clearasil sales continue to improve in response to increased marketing support and launches of new product lines, Boots states. Firm currently is rolling out Clearasil Total Control, a non-acne skin care line expected to generate $32 mil. in first year U.S. sales (2"The Rose Sheet" Dec. 16, 2002, p. 3). As part of company's increasing focus on core businesses, Boots the Chemists and Boots Healthcare International, Boots will exit Pure Beauty concept, which currently consists of six stores in the UK, firm says...
You may also be interested in...
Clearasil Launch Aims For Broader Control Of U.S. Skin Care Category
Boots Healthcare International is launching Clearasil Total Control, a non-acne treatment skin care range, to fill a void in the mass market for products that offer basic skin care benefits to young women, the company said during a press event in New York City Dec. 10
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.